Quantcast

Industry news that matters to you.  Learn more

Archives for January 2016

Biocartis and Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing

Biocartis, an innovative molecular diagnostics company, recently announced that Biocartis has signed a collaboration agreement with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis’ innovative, fully automated molecular diagnostics system, Idylla™, which is designed to offer accurate and reliable molecular information from virtually any biological sample in virtually any setting. The new test aims to support clinical practice in performing integrated liquid biopsy RAS biomarker tests, independently of the laboratories’ volume of testing or level of expertise.

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient’s blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

Emerging Biomarkers Disrupt Cardiac Diagnostics

Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for the diagnosis of cardiac diseases, end users will soon see additional alternative biomarkers entering the market. By 2024, emerging biomarkers, such as ST2 Galectin-3, are becoming more sensitive in diagnosing cardiovascular disease will penetrate the lab-based and point-of-care (POC) end user segments.

Biodesix’ GeneStrat Blood-Based Mutation Test Now Includes EML4-ALK Fusions

Biodesix, Inc. recently announced that the GeneStrat™ blood-based panel now includes EML4-ALK fusions in addition to EGFR sensitizing, EGFR T790M, KRAS, and BRAF mutations. GeneStrat is a non-invasive, blood-based test analyzing circulating tumor DNA and RNA, designed to provide fast, accurate results in 72 hours for newly diagnosed non-small cell lung cancer (NSCLC) patients.